bisoprolol has been researched along with Kidney Diseases in 3 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
Excerpt | Relevance | Reference |
---|---|---|
" In healthy subjects peak and trough steady-state concentrations of 52 micrograms/L and 11 micrograms/L, respectively, an elimination half-life of 10." | 1.27 | Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. ( Demers, HG; Kirch, W; Leopold, G; Ohnhaus, EE; Pabst, J; Rose, I, 1987) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (33.33) | 18.7374 |
1990's | 1 (33.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Watanabe, H | 1 |
Iwanaga, Y | 1 |
Miyaji, Y | 1 |
Yamamoto, H | 1 |
Miyazaki, S | 1 |
Uehara, Y | 1 |
Takada, S | 1 |
Hirawa, N | 1 |
Kawabata, Y | 1 |
Ohshima, N | 1 |
Numabe, A | 1 |
Ishimitsu, T | 1 |
Goto, A | 1 |
Yagi, S | 1 |
Omata, M | 1 |
Kirch, W | 1 |
Rose, I | 1 |
Demers, HG | 1 |
Leopold, G | 1 |
Pabst, J | 1 |
Ohnhaus, EE | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446] | 81 participants (Anticipated) | Observational [Patient Registry] | 2017-11-02 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 other studies available for bisoprolol and Kidney Diseases
Article | Year |
---|---|
Renal denervation mitigates cardiac remodeling and renal damage in Dahl rats: a comparison with β-receptor blockade.
Topics: Adrenergic beta-Antagonists; Animals; Bisoprolol; Blood Pressure; Denervation; Hypertrophy, Left Ven | 2016 |
Vasoconstrictors and renal protection induced by beta 1-selective adrenoceptor antagonist bisoprolol.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Bisoprolol; Blood Pres | 1994 |
Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Blood Proteins; Half-Life; Hepatitis; Humans; Kidney | 1987 |